Berenberg analyst Victoria Lambert initiated coverage of Richter Gedeon with a Buy rating and HUF 9,980 price target. The company is best known for its original blockbuster drug Vraylar, which it sells in partnership with AbbVie in the U.S., the analyst tells investors in a research note. The firm says the market is underappreciating the earnings upside potential from Vraylar.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEDF: